3rdPartyFeeds

Eli Lilly’s quarter was messy. What to do with the stock is more clear-cut

We're upgrading our rating on the drugmaker to a buy-equivalent 1. Read more...

Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.

Cristina Arias | Cover | Getty Images

Eli Lilly shares fell Wednesday after the diabetes-and-obesity drug giant posted disappointing third-quarter results and lowered its full-year sales guidance. The report was messy, but it doesn’t dim Eli Lilly’s bright multiyear outlook, rendering the dip in the stock as a chance to buy.

Read more

Add Comment

Click here to post a comment